Rapidly developing Blockchain technology can deliver transparent, secure and reliable data sharing. It also has the prospect of streamlining business processes, saving on costs and building trusted relationships with stakeholders. But what are the risks to healthcare inherent with blockchain […]
Benchmarking Market Access Strategies for High-Cost Drugs and Biologics
What is the secret of commercial success for high cost specialty drugs? More specifically, what do the companies that overcome affordability and value demonstration issues do differently? There are lots of strategies that are generating results. This report explores the key issues — and delves into […]
HTA in Europe: Key Success Factors for Positive HTA Recommendations
Via FirstWord Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on the increase, and market access professionals are scratching their heads wondering what can realistically be done to ease the […]
Paying for Digital Health: Payer Insights
Digital technology is revolutionizing health care from advanced electronic medical records and telemedicine to emerging technologies such as smart pills/inhalers and 3D dose printing. Great stuff, but payers are only interested in value. Where there is evidence that digital technology delivers […]
Benchmarking Pharma’s MSL Capabilities
Are you convinced your MSL teams are keeping up with evolving market practice? The best medical science liaison (MSL) teams have made significant changes to adapt to a whole new world. The pharma companies getting the best results from their MSLs have been busy: widening their remit, embracing […]
Biosimilars: US Payer Perspectives
Biosimilars may be a roaring success in Europe but the picture in the U.S. couldn't be more different. Once hailed as a solution to stem the tide of soaring drug spending, in the cold light of day, the U.S. biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle of […]
KAM Metrics: Driving Efficiency, Measuring Success
The maturing key account management (KAM) model has transformed the way customer-facing teams operate: the challenge now is to use metrics that reflect the diversity of these sophisticated relationships and drive them forward. But what works for one contact or KAM may not be appropriate for the […]
Biosimilars: E.U. Payer Perspectives
Biosimilars: EU Payer Perspectives gives the inside track on the biosimilars market today, offering new information to help you stay ahead. For this report, we've spoken directly to 10 high-profile payer decision-makers and reimbursement influencers across Europe. These are the people who define […]
MSL Teams: Field Force Size and Structure
Medical Science Liaison (MSL) personnel play an ever crucial and widening role in communicating the value and science of increasingly complex therapies to opinion leaders and stakeholder groups. The challenge for senior management is to ensure their MSL teams are optimally provided for in terms of […]
Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017
Market barriers affect a staggering 39 percent of prescriptions for injectable treatments for Type 2 Diabetes Mellitus in the U.S. According to the diabetologists and primary care physicians we surveyed, that’s a problem with no single solution. Many of them experience as many as 2 different […]
Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) 2017
Market barriers affect a staggering 37 percent of prescriptions for oral treatments for Type 2 Diabetes Mellitus in the U.S. According to the diabetologists and primary care physicians we surveyed, that’s a problem with no single solution. Many of them experience as many as 2 different barriers with […]
Market Access Impact: Rheumatoid Arthritis (US) 2017
Who wins and loses when brands struggle with cost barriers and limited market access? Market barriers affect just over 20 percent of rheumatoid arthritis (RA) prescriptions in the U.S. High costs and limited formulary access are preventing rheumatologists we surveyed from prescribing some brands. […]
Pricing and Reimbursement in Oncology: Payer views
As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10 percent every year between 1995 and 2013. That level of price inflation is not sustainable or winning pharma any friends. In this expert report, U.S. and E.U. payers […]
The ROI of Orphan Drugs: Ensuring Optimal Returns
Orphan drugs are at the forefront of medical science and offer a chance for the pharma industry to make a real difference to people's lives; there's also the lure of potentially lucrative commercial benefits for those that succeed. But finding the right balance between return on investment (ROI) and […]
New Syndicated Report – Orphan Drug Launch Strategies: Case Studies
Compared to mainstream drug launches, it's usually a much smaller team with fewer resources that are tasked with bringing a new orphan drug to market. And the market itself is smaller too – fewer specialists to talk to, fewer physicians to educate, and fewer patients to engage with. But smaller […]
New Syndicated Report: 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers remains the most comprehensive, fact-based analysis of the evolving drug channels within the U.S. healthcare system. It’s your ultimate guide to the complex web of interactions within the U.S. prescription distribution and […]
Market Access Team Structure and Function: Industry Survey 2017
New syndicated report available
This report gives a unique insight into how U.S. and European market access teams are organized and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017 draws on detailed survey responses from 100 market access executives within the […]
Patient-Centered Risk Assessments – A Key Ingredient of Value-based Care
New white paper by Sandra Hewett
Download this white paper to learn how Jiva’s Clinical Assessment Protocols (CAPs) provide greater support for value-based care initiatives than traditional health risk assessments. By going beyond clinical details of chronic conditions to assess psychosocial health determinants, the […]
The Future of Market Access in the U.S.
When it comes to the affordability challenge, have payers and drugmakers reached a stalemate in the U.S.? Pricing wars continue to rage, pharma initiatives are having lackluster impact, and payers are still not happy. At the same time, U.S. President Donald Trump is waxing lyrical about sweeping […]
New Syndicated Report: The Future of Market Access in Europe
"The Future of Market Access in Europe" takes a step into the ongoing debates about the challenges and obstacles still facing market access in Europe. "Payers and health-technology assessment agencies at multiple levels of healthcare systems have a growing influence on market-access conditions for […]
Syndicated Report: Biomarkers and Companion Diagnostics — Payer views
How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the personalised medicines agenda. They support clinician decision making and are cost efficient for payers. But payers identify challenges around evidence of […]
Syndicated Report: Why Pharma Needs to Get Serious about Data
"In today’s highly scrutinized drugs marketplace, pockets continue to be squeezed and the list of demands from every quarter lengthens. Against this challenging backdrop, every decision made must be backed up by evidence. But exactly what evidence is required by whom, and how should it be […]
Syndicated Report Available: How Payers Want to Work with Pharma
A recently-published syndicated report titled "How Payers Want to Work with Pharma" aims to bolster relations between the pharmaceutical industry and payers. The payer-led report takes aim at an industry which payers say can too often fall short on disclosure of all relevant material, or provide an […]
Syndicated report: The Future of Biosimilars in Europe
Future of Biosimilars: Europe (2017) offers a step by step walkthrough of key developments in the European biosimilars market, as well as future challenges and opportunities. 11 respected industry experts weigh in on adoption and pending approvals, policy and regulation, the evolving role of payers […]
Syndicated report: World Preview 2017, Outlook to 2022
The new edition of EvaluatePharma World Preview 2017, Outlook to 2022 takes an in-depth look at how drug sales are being impacted by more scrutiny around pricing. Some key highlights in the report: — Worldwide prescription drug sales forecasted to grow at a robust 6.5 percent (CAGR) through 2022 […]
How Can MSL Performance be Measured Effectively?
MSL Metrics: Measuring Success is essential reading for MSL managers and practitioners. This report is based on the insight and experience of 9 MSL professionals working in or with top 25 pharma companies in the US and Europe. Packed with case studies and actionable information this study identifies […]
Medical Writing: The Backbone of Clinical Development
The Future of Medical Affairs
In this strategic report, The Future of Medical Affairs, senior medical affairs experts from leading pharma companies peer into the crystal ball to identify the future challenges innovative practices and technologies that will shape future operations in this critical sector. Find out more here. […]
Value-Based Healthcare: Making it Happen
How can Pharma help healthcare providers deliver value-based healthcare (VBHC)? Successful companies have learned that strong relationships, built on trust, are the key to lasting partnerships. The case studies in Value-Based Healthcare: Making it Happen show you how 3 pharma companies came to play […]
Pricing and Market Access – Facts Versus Fiction
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities (NMEs) in 2015. The Outlook offers expert insight into what we can learn from these results against […]
